News Sentiment

MTVA sentiment intelligence

MetaVia Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.78 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+20.3% over one week, +2.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 20.3% Price confirming higher
Trend fit Trend inactive 2.3% over four weeks
Fair value -92.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 32
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 8
Market source 6
Quartr 5
Moomoo 4
PR Newswire 4
Zacks Small Cap Research 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 15
Analyst action 9
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
StocksToTrade Direct company coverage

MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone

MetaVia Inc.'s stock (MTVA) surged by approximately 11% after the company announced a significant milestone in its phase 1 obesity drug trial for DA-1726, with all active patients completing dose titration. This early success has fueled strong trading interest and volatility in t

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 17:39
Source
StocksToTrade
Quartr Direct company coverage

MetaVia (MTVA) Emerging Growth Virtual Conference Summary

This article summarizes MetaVia's Emerging Growth Virtual Conference, highlighting the significant market opportunities in cardiometabolic diseases like obesity and MASH. It details clinical developments for DA-1726 and Vanoglipel, showcasing their efficacy and safety profiles. T

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 19:44
Source
Quartr
Quartr Direct company coverage

MetaVia (MTVA) Q4 2025 earnings summary

MetaVia (MTVA) reported significant progress in its cardiometabolic portfolio in Q4 2025, with positive Phase 1 data for DA-1726 for obesity and Phase 2a results for vanoglipel in MASH. The company also strengthened its intellectual property. Financially, MetaVia reduced its net

Tone
Positive 70/100
Event
Earnings
Published
11 Jul 2026 06:41
Source
Quartr
Quartr Direct company coverage

MetaVia (MTVA) Investor presentation Summary

MetaVia's investor presentation on March 26, 2026, highlighted significant market opportunities in obesity and MASH, projecting substantial market values by 2030. The company presented promising clinical progress for its drug candidates, DA-1726 and Vanoglipel, showcasing their e

Tone
Positive 77/100
Event
Market update
Published
11 Jul 2026 06:39
Source
Quartr
Quartr Direct company coverage

MetaVia (MTVA) Emerging Growth Conference 93 Summary

MetaVia (MTVA) presented a summary of its Emerging Growth Conference 93, highlighting key clinical updates for DA-1726 and vanoglipol. DA-1726 showed no heart rate abnormalities and a "textbook-like" PK profile, with Phase I part three ongoing. Vanoglipol met primary endpoints in

Tone
Positive 67/100
Event
Market update
Published
11 Jul 2026 01:39
Source
Quartr
Moomoo Direct company coverage

Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8

Maxim Group has reiterated its Buy rating for MetaVia (MTVA.US) and maintained its price target at $8. This indicates continued confidence from the analyst firm in the company's performance and future prospects.

Tone
Positive 75/100
Event
Analyst action
Published
10 Jul 2026 20:11
Source
Moomoo
Investing.com Canada Direct company coverage

H.C. Wainwright reiterates MetaVia stock rating on dose milestone By Investing.com

H.C. Wainwright has reiterated its Buy rating and a $20.00 price target for MetaVia (NASDAQ:MTVA) after the company announced that all active patients in its Phase 1 clinical trials for the obesity treatment DA-1726 successfully reached the highest target doses. While this dose e

Tone
Positive 70/100
Event
Analyst action
Published
10 Jul 2026 12:09
Source
Investing.com Canada
scanx.trade Direct company coverage

MetaVia reaches highest target doses in Phase 1 obesity trial

MetaVia Inc. has announced that all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment, have successfully completed dose titration and are now receiving the highest target doses of 48 mg and 64 mg. This progress keeps the company on track to

Tone
Positive 75/100
Event
Analyst action
Published
09 Jul 2026 14:39
Source
scanx.trade
Investing.com Direct company coverage

MetaVia completes dose titration in obesity drug trial

MetaVia Inc. announced that all active patients in Part 3 of its Phase 1 clinical trial for the obesity treatment candidate DA-1726 have completed dose titration, reaching target doses of 48 mg and 64 mg. The trial evaluated different dose-escalation strategies in approximately 4

Tone
Positive 66/100
Event
Analyst action
Published
09 Jul 2026 13:39
Source
Investing.com
PR Newswire Direct company coverage

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Inc. announced the successful completion of dose titration for all active patients in Part 3 of its Phase 1 clinical trial of DA-1726, an oxyntomodulin analog for obesity treatment. Patients in both cohorts have reached their highest target doses of 48 mg and 64 mg, indic

Tone
Positive 71/100
Event
Analyst action
Published
09 Jul 2026 12:39
Source
PR Newswire
TradingView Direct company coverage

MetaVia completes dose titration in Phase 1 Part 3; topline data on track for Q4 2026

MetaVia has announced the completion of dose titration for all active patients in Phase 1 Part 3 of its clinical trial, with patients reaching target doses of 48 mg and 64 mg. The company utilized two titration cohorts to optimize tolerability. Topline data for this part of the s

Tone
Positive 71/100
Event
Analyst action
Published
09 Jul 2026 12:39
Source
TradingView
Stock Titan Direct company coverage

MetaVia (NASDAQ: MTVA) completes DA-1726 Phase 1 dose titration milestone

MetaVia Inc. announced the successful completion of dose titration for all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment. Patients are now receiving the highest target doses of 48 mg and 64 mg, indicating favorable tolerability and effi

Tone
Positive 65/100
Event
Analyst action
Published
09 Jul 2026 12:39
Source
Stock Titan
Moomoo Direct company coverage

MetaVia(MTVA) Stock Options Chain | Quotes & News

The article provides information related to MetaVia (MTVA) stock, specifically focusing on its options chain, quotes, and news. It indicates that the content is a document, suggesting it contains detailed data or reports regarding MTVA's financial instruments and market performan

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 06:09
Source
Moomoo
Investing.com UK Direct company coverage

Form 424B5 MetaVia Inc For: 2 July By Investing.com

This article from Investing.com reports on the filing of Form 424B5 by MetaVia Inc. on July 2, 2026. The brief entry provides the company name and the filing date, indicating a regulatory update related to MetaVia Inc. The article is very concise, primarily serving as a notificat

Tone
Neutral 50/100
Event
Regulatory and legal
Published
02 Jul 2026 21:20
Source
Investing.com UK
Stock Titan Direct company coverage

Metavia (NASDAQ: MTVA) ups ATM offering limit to $4.0M

Metavia Inc. (NASDAQ: MTVA) has increased its At-The-Market (ATM) offering limit to $4.0 million, up from a previous ceiling of $2.3 million. The company has already sold $2,126,303 of common stock under the sales agreement with Ladenburg Thalmann & Co. Inc. This move expands Met

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

[8-K] MetaVia Inc. Reports Material Event

MetaVia Inc. has filed an 8-K report announcing a prospectus supplement related to its existing "at-the-market" equity program. The company may sell up to $4,000,000 of common stock through Ladenburg Thalmann & Co. Inc. The filing includes a legal opinion from Honigman LLP regard

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
TradingView Direct company coverage

MetaVia Inc. Financial Disclosures & SEC Filings

This article provides a comprehensive list of MetaVia Inc.'s financial disclosures and SEC filings, including quarterly and annual reports, earnings releases, and investor presentations from 2023 to 2026. These documents detail the company's clinical progress, financial performan

Tone
Positive 65/100
Event
Earnings
Published
01 Jul 2026 09:10
Source
TradingView
Zacks Small Cap Research Direct company coverage

OTC Markets Hosts Virtual Investor Presentation with HH Kim, CEO and President, and Marshall Woodworth, CFO of MetaVia, with David Bautz, PhD, Senior Analyst at Zacks SCR

MetaVia's CEO, HH Kim, and CFO, Marshall Woodworth, discussed their strategic vision with Zacks SCR's David Bautz, focusing on their obesity drug DA-1726 and MASH drug danuglipron. They highlighted DA-1726's GLP-1/glucagon dual agonism, aiming for a favorable balance to minimize

Tone
Positive 74/100
Event
Analyst action
Published
30 Jun 2026 22:10
Source
Zacks Small Cap Research
Market source Direct company coverage

OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz

MetaVia's CEO HH Kim and CFO Marshall Woodworth discussed the company's strategic vision, focusing on obesity and MASH treatments. They highlighted the dual-agonist drug DA-1726 for obesity, emphasizing its GLP-1/glucagon balance and promising early clinical data with fewer side

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 15:39
Source
Market source
Moomoo Direct company coverage

MetaVia (MTVA) Stock Forum and Discussion

This article provides a forum for discussion and information sharing regarding MetaVia (MTVA) stock. It likely serves as a community platform for investors to exchange views, analysis, and news related to the company's financial performance and market outlook.

Tone
Neutral 50/100
Event
Guidance
Published
28 Jun 2026 02:09
Source
Moomoo
TradingView Direct company coverage

Enterprise value to EBITDA forward of MetaVia Inc. – NASDAQ:MTVA

This article provides a financial observation on MetaVia Inc. (NASDAQ: MTVA) focusing on its enterprise value to EBITDA forward metric. The content directly displays this specific financial ratio for the company, indicating a focus on fundamental analysis.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 15:10
Source
TradingView
TradingView Direct company coverage

MetaVia Inc. Actuals & Estimates (NASDAQ:MTVA)

This article provides an overview of MetaVia Inc. (NASDAQ: MTVA) stock, including its current price, market capitalization, performance trends, and analyst forecasts. It details financial actuals and estimates, along with key information such as earnings reports, revenue, net inc

Tone
Negative 34/100
Event
Earnings
Published
26 Jun 2026 14:12
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of MetaVia Inc. – NASDAQ:MTVA

This article provides a financial snapshot for MetaVia Inc. (NASDAQ: MTVA), focusing on its enterprise value to revenue forward metric. It details that the market for MTVA is closed with no trades, offering a general overview of its financials within the biotechnology and health

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of MetaVia Inc. – NASDAQ:MTVA

This article provides the "Price to sales forward" value for MetaVia Inc. (NASDAQ: MTVA). It lists the period, value, change, and percentage change. The data is presented in a table format indicating it was "Made by humans."

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 01:40
Source
TradingView
TradingKey Direct company coverage

MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

TradingKey provides an earnings forecast for MetaVia Inc (MTVA), detailing analyst ratings, price targets, and past and projected EPS. Based on two analysts, MetaVia Inc receives a "Buy" rating with a target price indicating significant upside potential. The report also lists pee

Tone
Positive 70/100
Event
Earnings
Published
17 Jun 2026 21:11
Source
TradingKey
TradingKey Direct company coverage

MetaVia Inc (MTVA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for MetaVia Inc (MTVA), detailing its current stock price, market cap, and highlighting that relevant data for key valuation metrics like P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. It notes the stock's recent per

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:11
Source
TradingKey